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OBJECTIVES: Patients with Clostridium difficileinfection (CDI) can experience long-
term symptoms that resemble a chronic disease state. Despite this, a health-related 
quality of life (HRQOL) instrument specific for patients with CDI does not exist. 
The goal of this study was to develop and validate a disease specific instrument to 
assess HRQOL in patients with CDI. METHODS: A systematic literature review was 
conducted to identify HRQOL instruments and questions related to general health 
(n= 3) or gastrointestinal disease (n= 13) related to CDI HRQOL. Removing duplicate 
questions and using direct patient (n= 10) or clinician (n= 10) interviews, a 36-item 
survey specific to CDI HRQOL was developed. Test-retest and acceptability of item 
selection was tested on 20 CDI patients and 20 healthy volunteers. The Cdiff36 
HRQOL survey was then tested using 100 patients with CDI and compared to the 
RAND Short-Form 36 (SF-36) Health Survey. Domains containing questions with a 
correlation coefficient of > 0.7 were considered acceptable. To compare population 
average scores for patients with CDI, the SF-36 was also administered to 82 patients 
given broad-spectrum antibiotics. RESULTS: SF-36 scores were significantly higher 
in healthy controls (72±22) compared to patients on broad-spectrum antibiotics 
(54±12) or patients with CDI (43±17); p< 0.05 each vs. control. The final version of 
the Cdiff36 contained six domains: daily activities (4 items), anxiety (3 items), diet 
(3 items), sleep (2 items), discomfort (6 items), health perception (6 items), dys-
phoria (6 items), relationship (2 items), and social interaction (3 items). CDiff36 
scores correlated significantly based on recurrence vs. primary CDI as well as time 
since last episode (p< 0.05, each). Cdiff36 scales also correlated significantly with the 
SF-36. CONCLUSIONS: The properties of the Cdiff36 should make it appropriate to 
assess changes over time in HRQOL in patients with CDI. Future language transla-
tions and validation will be required for global use of the CDiff36.
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OBJECTIVES: The Food and Drug Administration’s (FDA) clinical trial guidelines for 
development of patient reported outcome (PRO) instruments recommends deriving 
the PRO concepts from the target population using qualitative research. Since the 
PRO instruments currently used in clinical trials of hepatitis C (HCV) patients are 
not developed specifically for this patient population, the FDA’s recommendation 
is not fulfilled. The purpose of this study was to identify a comprehensive list of 
health related quality of life (HRQoL) themes that may be unique to HCV by review-
ing qualitative studies of HCV patients. METHODS: Ovid Medline, Ovid Embase, Ovid 
PsycINFO, and PubMed were searched for peer-reviewed journals from 1946 to 2012. 
Inclusion criteria required primary studies to include HCV patients; be published 
in English; and used qualitative methods to report an aspect of the HCV experi-
ence. Studies were excluded if secondary data was used or there were proxy views. 
Included studies were graded on study quality using the Qualitative Assessment 
and Review Instrument. Eligible studies were then analyzed using meta-synthesis; 
findings from individual studies were grouped into themes which were combined to 
generate HRQoL domains. RESULTS: Ten studies met the inclusion/exclusion crite-
ria and the quality assessment criteria and were included for review. Eleven themes 
were identified: physical symptoms, physical activities, guilt, stigma, emotional 
distress, psychological behavior, social relationship, social activities, work func-
tion, sexual function, and cognitive function. The type of themes identified in each 
study varied by the focus of the primary study and the analytical framework used in 
the qualitative studies. The themes were further grouped into six HRQoL domains: 
physical, psychological/emotional, social, work, sexual, and cognitive functional-
ity. CONCLUSIONS: The systematic review represents a useful starting point in the 
critical appraisal of the PRO instruments used for clinical trials in HCV patients.
GaStroInteStInal dISorderS – Health care use & Policy Studies
PGI34
do PHySIcIanS cHanGe tHeIr PreScrIPtIonS In reSPonSe to fInancIal 
IncentIveS
Han E.1, Park S.2
1Yonsei University, Incheon, South Korea, 2Korea Institute of Health and Social Affairs, Seoul, 
South Korea
OBJECTIVES: We assessed the impact on prescription behaviors and drug expendi-
tures of an outpatient prescription incentive program in South Korea that provides 
financial incentives to primary care physicians for less prescription of medi-
cines. METHODS: We focused on drugs for ulcer or gastro-esophageal reflux disease. 
National Health Insurance claims data for years 2009~2012 were extracted from 
1,625 clinics. A clinic-level random effects model was used. RESULTS: The overall 
impact of the program on drug expenditure was not significant. However, clinics in 
general medicine showed a lower prescription rate (-0.8 percentage points), number 
of medicines prescribed (-0.02), prescription duration (-0.15 days), and monthly 
drug expenditure (-740 won) per claim after the policy. Small clinics had lower drug 
expenditure (-650 won) and prescription duration (-0.76 days), while large clinics and 
those in group practice had higher prescription rate (+1.5 and 2.5 percentage points, 
respectively) and number of medicines prescribed (+0.03, group practice only) after 
the policy. CONCLUSIONS: The outpatient prescription incentive program worked 
as intended only in subgroups of minor clinics for the target medicines.
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self-care, or usual activities; 15.8% and 16.5% reported pain/discomfort and anxiety/
depression, respectively. The mean (standard deviation) global health score was 
83.5 (13.3) on a 0 (worst) to 100 (best) scale. Independent predictors of reporting any 
of the EQ-5D health problems included female gender, BMI 25-30 kg/m2, presence 
of comorbidity (hypertension, hyperlipidemia, etc.), family history of liver cancer, 
albumin < 28g/L, and HBeAg positive. Alcohol drinking, a diagnosis of CHB for > 15 
years, and presence of comorbidity were independent predictors of a lower global 
health score, with the effect size ranging between 1 and 4 points. CONCLUSIONS: 
CHB characteristics showed some association with patient-reported health prob-
lems, but their association with general health perception was minimal. The modest 
relationship between clinical and patient-reported outcomes measures supports 
the assessment of patient-reported outcomes in patients with CHB.
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OBJECTIVES: The impact on patient HRQoL of including ribavirin (RBV) in interferon-
free hepatitis C virus (HCV) treatment has not been determined. We assessed the 
HRQoL impact of an all-oral HCV therapy, ombitasvir/paritaprevir/ritonavir and das-
abuvir (OBV/PTV/r+DSV), with and without RBV in treatment naïve, non-cirrhotic, 
GT1a adults at the end of 12-week treatment in Phase 3 PEARL-IV trial. METHODS: 
HCV patients were randomized in a 1:2 ratio to OBV/PTV/r+DSV with RBV or OBV/
PTV/r+DSV without RBV and treated during a 12-week double-blind period. HRQoL 
was assessed using the SF-36v2 Health Survey (SF-36) which was administered 
to patients at baseline, during treatment, at end of treatment (EOT) and at post-
treatment (PT) visits. Physical Component Summary (PCS) and Mental Component 
Summary (MCS) scores were calculated for the SF-36. The statistical significance of 
differences between treatment groups in mean change from baseline to EOT was 
assessed. RESULTS: The analysis included 100 patients on OBV/PTV/r+DSV with 
RBV and 205 on OBV/PTV/r+DSV without RBV. At EOT, mean±SD decrements from 
baseline PCS and MCS scores were observed in the RBV group (change of -0.6±7.19 
in PCS and -2.9±10.55 in MCS) while small increases were observed in the non-RBV 
group (change of +0.9±7.01 in PCS and +0.3±10.09 in MCS). The difference in mean 
change from baseline to EOT did not reach statistical significance for either PCS 
(p-value= 0.105) or MCS (p-value= 0.063). At PT week 24, mean changes from baseline 
were 2.4±5.19 in PCS and 2.6±6.99 in MCS in the RBV group, and 2.2±7.00 in PCS and 
2.0±10.94 in MCS in the non-RBV group. CONCLUSIONS: At the end of 12-week 
treatment in PEARL-IV, the addition of RBV to the interferon-free all-oral OBV/PTV/
r+DSV regimen did not have a significant impact on patient HRQoL in treatment-
naïve GT1a patients. After treatment, PCS and MCS scores for both treatment groups 
showed similar improvement over baseline.
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OBJECTIVES: An all-oral HCV therapy, ombitasvir/paritaprevir/ritonavir and dasa-
buvir (OBV/PTV/r+DSV), without ribavirin (RBV), has been approved by the Food and 
Drug Administration (FDA) for treatment of treatment naïve, non-cirrhotic, GT1b 
adults. We report the HRQoL impact of OBV/PTV/r+DSV, with and without RBV, after 
12-week treatment in the Phase 3 PEARL-III trial. METHODS: HCV patients were ran-
domized in a 1:1 ratio to OBV/PTV/r+DSV with RBV or OBV/PTV/r+DSV without RBV 
and treated during a 12-week double-blind period. HRQoL was assessed using the 
SF-36 v2 Health Survey (SF-36) which was administered to patients at baseline, dur-
ing treatment, at end of treatment (EOT) and at post-treatment (PT) visits. Physical 
Component Summary (PCS) and Mental Component Summary (MCS) scores were 
calculated for the SF-36. The statistical significance of differences between treat-
ment groups in mean change from baseline to EOT was assessed. RESULTS: The 
analysis included 210 patients on OBV/PTV/r+DSV with RBV and 209 on OBV/PTV/
r+DSV without RBV. Among non-cirrhotic subjects with GT1b infection who were 
treated with OBV/PTV/r+DSV without RBV, almost no decrements from baseline 
PCS or MCS scores were observed at EOT (changes [mean±SD] of -0.1±6.71 in PCS 
and -0.1±9.09 in MCS). The decrements OBV/PTV/r+DSV with RBV were numerically 
larger (-0.5±6.80 in PCS and -1.4±9.15 in MCS); however, differences from the non-
RBV group were not statistically significant for either PCS or MCS (p-value= 0.348 
in PCS and p-value= 0.150 in MCS). At PT week 24, mean changes from baseline 
were 1.0±6.20 in PCS and 1.9±8.40 in MCS in the non-RBV group 0.9±6.04 in PCS and 
1.8±7.40 in MCS in the RBV group. CONCLUSIONS: At the end of 12-week treatment 
in PEARL-III, the interferon-free all-oral OBV/PTV/r+DSV regimen in treatment-
naïve GT1b patients had negligible impact on patient HRQoL, regardless of whether 
RBV was co-administered. After treatment, PCS and MCS scores for both treatment 
groups showed similar improvement over baseline.
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a systematic monitoring, as in pharmaceutical care services, seeking to promote 
safety of pharmacotherapy.
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OBJECTIVES: To study the risk of nephrotoxicity and the cost of treatment of colis-
tin. METHODS: Patients admitted in ICU with resistant bacterial infections and on 
colistin for at least seven days were included in the study. They were observed for 
any change in Glomerular filtration rate and the risk of nephrotoxicity according 
to the RIFLE criteria after the colistin therapy. The GFR values before the initiation 
of treatment with colistin were compared with that after the end of regimen. The 
pre and post treatment GFR values were compared using non-parametric Wilcoxon 
Signed Ranks test. RESULTS: A total of 30 patients on colistin were observed dur-
ing the study. The mean age of the patients was 45.47±16.45. The average APACHE 
II score was 15.87±5.82. There was no significant difference between the GFR of 
patients before and after treatment with colistin (p= 0.130). The average hospitali-
zation cost was 255245.41±138099.29 and the average cost of colistin therapy was 
31638.10±12625.90. CONCLUSIONS: This study showed that the nephrotoxic effect 
of colistin is not significant. There is a need to conduct more studies with a higher 
sample size to assess the risk of colistin-induced nephrotoxicity. The incidences 
of nephrotoxicity in the patients studied can be attributed to various other factors 
such as age, comorbidities etc. The cost of colistin therapy was substantial being 
more than one-tenth of the total hospitalization cost.
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OBJECTIVES: Invasive candidiasis is an important cause of complication and mor-
tality of inpatient. Anidulafungin as others echinocandins are drugs that have 
shown clinical relevance in the treatment of invasive candidiasis. This research 
sought to evaluate the effectiveness and safety of anidulafungin in comparison 
to fluconazole, amphotericin B deoxycholate, amphotericin B liposomal, caspo-
fungin and micafungin for the treatment of invasive candidiasis among non-neu-
tropenicpatients above 16 years. METHODS: We performed a systematic review 
in which were included randomized clinical trials (RCT) evaluating the different 
drugs to treatment of invasive candidiasis in non-neutropenic patients. It involved 
in MEDLINE, EMBASE, Cochrane, DARE and LILACS. The quality of evidence and risk 
of bias of clinical trials were assessed with GRADE tool and Cochrane methodol-
ogy respectively. We performed a meta-analysis and Bayesian mixed treatment 
comparison (MTC) to compare the effectiveness and safety of the different con-
sidered treatment. The outcomes of effectiveness and safetywere global response 
rate, mortality and occurrence serious event adverse (SEA). RESULTS: We included 
11 RCT and clinical evidence provided was of moderate quality according to the 
GRADE system. For global response rate, the MTC displayed that anidulafungin 
was more effective than fluconazole (OR 2.07 IC95% 1.20- 2.59). In comparison with 
others drugs, anidulafungin presented similar effectiveness (non-significant sta-
tistically differences). In mortality, it presented less proportion of events (29,5% 
IC95% 18,8-42,0) than other interventions, but it was not statistically different of 
them. Anidulafungin showed better safety profile than amphotericin B deoxycholate 
regarding to occurrence of SEA (OR 0.15 IC95% 0.02-0.97). However, there were not 
significantly statistical differences with amphotericin B liposomal, caspofungin and 
fluconazole. CONCLUSIONS: The MTC found that anidulafungin is more effective 
than fluconazole and exhibited similar effectiveness than others interventions. With 
respect to safety profile, anidulafungin was superior to amphotericin B deoxycolate 
and similar to the others.
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BACKGROUND: A landmark in the prevention of serious respiratory syncytial 
virus (RSV) infection was established with the release of palivizumab, a recom-
binant, humanized, genetically-engineered monoclonal antibody. Palivizumab 
has been deemed safe in clinical trials without major, serious adverse events 
(SAEs). OBJECTIVES: The primary objective of this study is to evaluate the safety 
and tolerability of palivizumab for RSV infection prophylaxis in high-risk chil-
dren. METHODS: High-risk children prophylaxed against RSV infection were 
recruited into a prospective, observational, Canadian RSV Evaluation Study of 
Palivizumab (CARESS) registry with active SAE monitoring from 2008 to 2013. SAE 
reports were systematically collected and assessed for severity and relationship to 
palivizumab. Data were analyzed by using Chi-square or Fisher Exact Tests to exam-
ine group differences in proportions. RESULTS: 13,025 infants were enrolled and 
received 57,392 injections: premature infants ≤ 35 weeks gestational age (n= 8224; 
63.1%), children aged < 2 years with chronic lung disease (n= 978; 7.5%), hemody-
namically significant congenital heart disease (n= 1442; 11.1%) and pre-existing 
medical disorders (n= 2381; 18.3%). 915 patients were hospitalized for a respiratory 
OBJECTIVES: To provide real-world evaluations of newer direct-acting antivirals 
(DAAs) in CHC patients from large US payer perspectives. METHODS: Medical and 
pharmacy claims linked to lab data from the Humana Database were analyzed for 
Medicare Advantage or commercially-insured adults with ≥ 2 CHC claims (ICD-9 
070.44; 070.54) who received therapy containing SMV and/or SOF through June 2014; 
those with HIV were excluded. Patients were grouped based on most common regi-
mens in the data: SMV/SOF, SMV/SOF/ribavirin (RBV), SOF/RBV, or SOF/interferon 
(IFN)/RBV; < 3% received other regimens. Baseline (BL) demographics and clinical 
characteristics (e.g., claims-based cirrhosis or end stage liver disease [ESLD], FIB-4 
scores) were described and post-treatment time measured. Methods to control for 
treatment selection bias were not performed, and comparative analyses were not 
conducted. RESULTS: There were 715 CHC patients who received therapy with SMV/
SOF (n= 184), SMV/SOF/RBV (n= 37), SOF/RBV (n= 269) or SOF/IFN/RBV (n= 225); mean 
age was between 60-62 years; 58%, 68%, 62% and 70% were male; most (85%, 78%, 
81% and 80%) had Medicare. For SMV/SOF, SMV/SOF/RBV, SOF/RBV, and SOF/IFN/
RBV groups, BL cirrhosis was present in 27%, 27%, 17%, and 24% of patients and 
ESLD in 48%, 38%, 27%, and 12% of patients, respectively. Slightly over half in each 
cohort had calculable FIB-4 scores, of which, 56%, 54%, 34% and 35%, respectively, 
had scores > 3.25. Among those with genotype data, 100% (78/78) SMV/SOF, 94.7% 
(18/19) SMV/SOF/RBV, 24.4% (29/119) SOF/RBV and 95.8% (92/96) SOF/IFN/RBV were 
genotype 1. Using prior claims history, 10%, 19%, 12% and 17% of respective cohorts 
were treatment-experienced. Less than half of each cohort had post-treatment data 
≥ 1 week. CONCLUSIONS: This analysis of CHC patients predominantly insured 
through Medicare found that the majority of those who received SMV/SOF +/- RBV 
had either cirrhosis or ESLD claims prior to therapy and, based on lab data, over 
half had FIB-4 scores > 3.25.
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OBJECTIVES: New Hepatitis C (HCV) antivirals have been shown to be highly effective 
with minimal side effects. These medications are costly and have raised significant 
concern from insurers, policymakers, advocacy groups, and patients about afford-
ability. However, little is known about the impact of new HCV antiviral expenditures. 
The objective of this study was to describe HCV antiviral expenditures by agent, 
year, and healthcare sector in the US. METHODS: HCV antiviral (interferon/ribavirin, 
telaprevir, simeprevir, sofosbuvir, boceprevir) expenditures from 10/1/2008-9/30/2014 
were obtained from the IMS Health© National Sales Perspectives database. This 
dataset represents a near-census view of US medication purchases. Expenditures 
were totaled by drug, sector, and year (defined as 10/1-9/30). Growth was calculated 
as the % increase compared to the previous year/period. RESULTS: A total of $12.2 
billion in HCV drugs were purchased from 10/2008-9/2014, 70.2% in 2014. HCV anti-
viral expenditures increased 10,880% over the six-years. Expenditures decreased by 
$7.8 million in 10/2012-9/2013 as compared to 10/2011-9/2012 (-41% growth). While 
the majority of expenditures in 10/2008-9/2010 were for interferons, this shifted to 
telaprevir in 10/2010-9/2013 and sofosbuvir in 10/2013-9/2014. Sofosbuvir was 55% of 
HCV drug expenditures over the study period and 78% in 10/2013-9/2014. By sector, 
mail order (59%) and retail (27%) pharmacies were associated with the majority of 
expenditures. CONCLUSIONS: New HCV antivirals are driving the increased expen-
ditures for this class. Decreased expenditures in 10/2012-9/2013 may have been 
secondary to delaying HCV treatment until new therapies received FDA-approval 
(“warehousing”). With continued drug development and approval of HCV therapies, 
expenditures are expected to continue to increase, barring actions by payers that 
may impede this trend. Medication policies guiding HCV treatment should focus on 
safety and efficacy while balancing the long-term costs of HCV. With the majority of 
expenditures originating from outpatient pharmacies, pharmacists are an essential 
partner to ensure appropriate use.
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OBJECTIVES: Adverse Drug Reactions (ADR) are one of the main problems related 
to antiretroviral (ARV) therapy and often result in decreased adherence and thera-
peutic failure. This study aimed to analyze the ADR that manifested during the 
Pharmacotherapeutic Monitoring (AFT) of HIV+ patients. METHODS: This was 
a longitudinal study carried out in accordance to the Dader Method of pharma-
ceutical care, which monitored 100 HIV+ patients in a center of medical spe-
cialties in Fortaleza-CE-Brazil, from November/2008 to January/2012. Data were 
collected from individual pharmacotherapeutic follow-up forms. The ADRs were 
classified according to causality as “definite, probable, possible, conditional and 
non-related” and gravity as “mild, moderate, severe and fatal”, using the World 
Health Organization (2002) method. RESULTS: Of the reported RAM (n = 267), the 
two most affected systems by ADR were the gastrointestinal tract (n = 117, ex. 
diarrhea, nausea and vomiting) and the nervous system (n= 101, ex. dizziness, 
nightmares and delusions). As for the classes of ARVs that were involved with ADR, 
the Nucleoside Reverse-Transcriptase Inhibitors (n = 113), followed by inhibitors 
non-Nucleoside Reverse-Transcriptase inhibitors (n= 73) observations and protease 
inhibitors (n = 49), were the most frequent. With regard to causality, 80.9% of RAM 
(n = 216) were classified as possible and 19.1% as probable (n = 51). As for gravity, 
85% (n = 176) were mild and 15% (n = 40) moderate. CONCLUSIONS: Data ratified 
that ARVs are triggers of ADR and its use need to be continually followed through 
